Pfizer Inc. has determined to discontinue improvement of its experimental weight problems tablet, danuglipron, following a case of potential drug-induced liver damage in a medical trial participant, which is a critical setback within the firm’s efforts to rival fashionable weight-loss therapies from Novo Nordisk and Eli Lilly.
Pfizer introduced that the once-daily tablet, which had been beneath shut scrutiny from traders, wouldn’t proceed to late-stage trials. As a substitute, the pharmaceutical large will redirect sources towards different early-stage weight problems drug candidates.
Tapping into the booming weight problems market has been a key a part of Pfizer’s technique to get better from declining COVID-related revenues. The worldwide marketplace for weight-loss therapies is projected to hit $130 billion by the tip of the last decade.
Nevertheless, Pfizer has struggled to maintain tempo. Eli Lilly’s Zepbound, a weekly injection, shortly generated near $5 billion in annual gross sales after its 2023 launch, and the corporate can be advancing its personal oral weight problems remedy. Different gamers like AstraZeneca and Construction Therapeutics are additionally pushing ahead with oral alternate options.
Pfizer had already deserted a twice-daily model of danuglipron because of excessive charges of nausea and vomiting that led most of the 1,400 contributors in a mid-stage trial to discontinue remedy. Previous to that, the corporate shelved one other weight problems tablet after observing troubling liver-related unintended effects throughout trials.
The choice places additional stress on Pfizer CEO Albert Bourla, who has constantly promoted the corporate’s drug pipeline as a key development engine. With a number of main medication set to lose patent safety by 2030—costing the corporate an estimated $15 billion in income—the failure to ship a blockbuster weight problems remedy is a major blow.
Regardless of a number of multi-billion greenback acquisitions aimed toward bolstering its portfolio, Pfizer’s inside R&D efforts have but to ship main successes. The corporate’s inventory has dropped over 60% since peaking through the pandemic in 2021.
Uncover the subsequent massive funding! Unicorn Indicators’ IPO screener helps you determine promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
